0.00Open0.15Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover6122.67%IV-19.05%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry0.15Time Value100Contract SizeAmericanOptions Type-0.3237Delta0.6734Gamma7.00Leverage Ratio-4.3735Theta0.0000Rho-2.27Eff Leverage0.0000Vega
Adaptimmune Therapeutics Stock Discussion
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade.
(Type of Cancer) Synovial Sarcoma : There are more than 50 different types of soft tissue sarcomas which are categorise...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
Abeona Therapeutics ( $Abeona Therapeutics(ABEO.US)$ )
Asset: Pz-cel (prademagene zamikeracel)
PDUFA Date: May 25, 2024
Indication: Recessive dystrophic epidermolysis bullosa (RDEB)
Technology: Autologous cell therapy, treatment uses gene transfer to deliver COL7A1 genes into an RDEB patient’s own skin cells then transplanting them back to the patient.
Rocket Pharmaceuticals ( $Rocket Pharmaceuticals(RCKT.US)$ )...
No comment yet